Vasomedical WKN 882846 Rebounder?!

Seit langem (2009) beobachte ich diesen Wert, habe meine Position entsprechend der Unternehmensereignisse immer weiter erhöht und werde dies, aus heutiger Sicht,  auch weiterhin tun.

Im Kerngeschäft geht es um eine nicht-invasive Behandlung diverser Herzleiden unter Ausnutzung der natürlichen Selbstheilungskräfte. Arteriogenese: der Spiegel berichtete bereits 2009 und 2010 über dieses Behandlungsverfahren. 

www.spiegel.de/spiegel/a-672723-2.html

Der in diesem Artikel verwendete Begriff  "Bio-Beipässe" lautet anders als der von VASO geschützte Begriff  "Natural Bypass", aktuell letzter Punkt in den FAQ.

www.vasomedical.com/investors-faq.php

In letzter Zeit verdichten sich die Indizien, daß VASO nach einer langen Periode finanziellen Leidens die Kurve gekriegt haben könnte:

1. Seit 2010 bestand ein "Sales-Agreement" mit GE-Healthcare welches Mitte 2012 bis zum Jahre  2015 verlängert wurde. Dieses Sales Agreement erlaubt VASO unter anderem den Vertrieb von bildgebenden Diagnoseprodukten von GE-H. Hierbei erhöhen sich die Einnahmen zum Jahresende aufgrund des retroaktiven Charakters der Prämien-Zahlungen wenn bestimmte Kalenderziele erreicht werden dessen Benchmarks mir unbekannt sind.
2. Seit dieser Vereinbarung hat das Unternehmen feste Einnahmen und erstaunliche Wachstumsraten welche, neben einer Aktien- Ausgabe, Akquisitionen im chinesischen Raum ermöglichten. Diese Akquisitionen führten zu  einer Erhöhung der Gewinnmargen (Zulieferer aufgekauft) und lassen auf Expansionsmöglichkeiten in neuen Märkten hoffen. "Our company is in the strongest financial position ever"
3. In diesem Jahr wechselte Randy Hill, Interim-CEO von Siemens Healthcare zu VASO. Dieser Mann hat eine  beeindruckende Vita für jemanden, der zu einer Firma mit einer Marktkapitalisierung von aktuell 29,93mio$ wechselt. Ehemals verantwortlich für 1650MA, leitet er nun den Vertrieb bei VASO.
4. Seit der letzten HV wurde die Firma Rothstein Kass and Company, P.C. mit dem externen Rechnungswesen betraut. In meinen Augen erhöht dies die Glaubwürdigkeit der bisher veröffentlichten Zahlen und erlaubt gleichzeitig eine Bündelung der Kapazitäten auf das Kerngeschäft.
5. Aktuell an den Pinks gelistet, liegt eine Bewerbung für die OTC-BB vor, welche die Aufmerksamkeit der Anlegergemeinde ungemein erhöhen könnte.
6. Am 5.12.2012 wurde an der staatl. Universität in Moskau ein EECP-Center eingerichtet. Studenten sollen diese Therapie kennenlernen. Vermutlich initiiert durch den rus. Distributor von VASO scheinen sich auch hier weitere Wachstumsmöglichkeiten zu ergeben.

 

Um eine eigene DD durchzuführen empfehle ich folgende Links:

 

 www.stock2own.com/StockAnalyzer.aspx

www.vasomedical.com 

 

eecp.com

finance.yahoo.com/q

www.externalcounterpulsation.com/difference-ecp-eecp-therapy

 

 

Ich freue mich über Kommentare, Anregungen und einen kooperativen Umgangston in diesem Thread.  

 

Natürlich keine Anlageempfehlung.

Ich selbst habe meine stücke in den USA gekauft. In DEU sind die Spreads irrwitzig und das Volumen (noch) viel zu gering.  

ih.advfn.com/p.php 

 

finance.yahoo.com/echarts 

 

hat denn hier keiner interesse dran??? das is mal echt kein saftladen wenn sich die dicken da so engagieren!??

k.c.s.a. wurde für IR angedacht. die nehmen auch nich jeden... (außer Sodastream :))

mal gucken wer hier recht behält.  

finance.yahoo.com/q/is 

 

da starte ich heut meinen ersten thread ever and new edgar online financials released... :) check these numbers

 

Vasomedical Common Stock Commences Trading on the OTCBB

15:05 10.12.12


PR Newswire

WESTBURY, N.Y., Dec. 10, 2012

WESTBURY, N.Y., Dec. 10, 2012 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical" or the "Company") (OTCBB: VASO) announced today that its shares of common stock have initiated trading via the Over-the-Counter Bulletin Board (OTCBB) under the ticker symbol "VASO".

The listing of the Company's common stock on the OTCBB follows FINRA's approval on December 3, 2012 of a 15c2-11 filing submitted by World Trade Financial Corporation, a market maker. For the initial 30 days of trading on the OTCBB there will not be a bid or ask displayed publicly for Vasomedical's common stock, given that there is only one market maker during this period, per the terms of the 15c2-11 filing. After the initial 30 days of trading on the OTCBB additional market makers can begin to make a market in the Company's stock and a bid and ask will then be available publicly for investors.  

"We are excited to initiate trading of our common stock on the OTCBB, which offers our company greater exposure to the investment community. The transition to the OTCBB is part of our broader IR strategy to gain additional investor awareness of Vasomedical and we expect to benefit from increased liquidity in the trading of our shares as a result of this new listing," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc.

The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter (OTC) securities. An OTC equity security generally is any equity that is not listed or traded on NASDAQ® or a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, American Depositary Receipts (ADRs), and Direct Participation Programs (DPPs).  The OTCBB is not an issuer listing service, market or exchange. Although the OTCBB does not have any listing requirements, to be eligible for quotation on the OTCBB, issuers must remain current in their filings with the SEC or applicable regulatory authority. Market Makers will not be permitted to begin quotation of a security whose issuer does not meet this filing requirement.

About Vasomedical

 

Freitag angekündigt :)

stay long 

 

gestern 320k traded shares, heute 70k bis jetzt. vaso braucht ne neue PR. während wir hier n neues Jahreshoch im Dax "feiern" ist von enthusiasmus keine spur. in amerika droht die fiskal klippe und in europa sind wir angeblich noch nen schritt weiter... . wenn den haussianern die standardwerte zu "teuer" werden, wird das geld in die nebenwerte überschwappen. meiner ansicht nach ist das ding hier unterbewertet sondergleichen.
time will tell!  

möchte sich einer derjenigen welchen, die diesen thread verfolgen nicht mal zu wort melden?
eine einschätzung abgeben, oder fragen anstoßen?

habe vor, alsbald meine position hier zu erhöhen. wenn andere mm hier mit dem trading beginnen wird erhöhte transparenz, meiner einschätzung nach, für steigende kurse verantwortbar sein. die vorhandene technologie hätte unglaubliches poten(z)tial, kosten im sich etablierenden gesundheitsheitssystem einzusparen... . meiner ansicht nach, ist das der grund für das rege interesse der big boys die hier indirekt involviert sind. vielleicht kloppen sich in noch ferner zukunft ge-h and siemens- healthcare mal um diesen nicht beachteten play.
good times ahead!?  

Found this post on another message board and wanted to share here
by norm11 . Dec 17, 2012 10:55 AM . Permalink


KCSA Strategic Comms (VASO's new IR Firm):

Spoke to someone at KCSA to get some questions answered...

1) We talked about the 2012 ACCF/AHA Clinical Guidelines, and reasons why they chose not to include current data to make their decision. This year's IIb rating, is based on 2008 data. I asked if Vasomedical is "appealing" the decision... his response was that ACCF/AHA meet at least twice a year (sometimes more?) to review new/improved data for medical therapies such as EECP. Based on our conversation, I've concluded that the company is, in fact, "appealing" so as to achieve a IIa rating. Other competing therapies were reduced to IIb, which for VASO, as previously mentioned in a PR, is good traction and positive...

2) Rios consultant. I expressed my frustrations with his up-front payment in diluted VASO shares, yet glad the company made all 5 goals performance based... Unfortunately, none of those 5 have been achieved, hence the need for a larger firm to "get the word out". Rios has until March to at least bat .200 My gut feeling is that ACCF/AHA is evaluating the "new" EECP data, and Rios and shareholders, will be pleasantly surprised just before baseball season begins.

3) We talked about share price... arrggggh! When will the bleeding stop? And who's selling? Obviously, he couldn't comment on this, but he did seem to indicate that this company is virtually UNKNOWN or "unwanted" due to past management failures and disappointments w/ investment community. Herein lies the reason for KCSA's existence. BTW, SODA (Nasdaq), was one of their babies, and they've done a pretty good job getting the word out to Wall St. with some of their other companies too.

4) My takeaway from our conversation? Positive. These guys (KCSA) seem like a quality group of professionals. Due to the nature of their relationship w/ VASO, they cannot invest in company stock (As it should be). They simply have a job to do, and I feel pretty confident they'll get the word out... It's only a matter of time.

Someone on the Yahoo board attended the shareholder meeting, and convinced me to buy more. So I'm back in the game w/ you guys.
Hope this helps,
Sunny

Sentiment: Buy  

Wurde anscheinend am 20.12. hochgeladen. Mehrere Videos über von und mit Vaso....

www.youtube.com/watch 

 

heut nochmal 5k nachgelegt. langsam darf se dann auch steigen...  

connect.kcsa.com/clientshowcase/item/2499-vasomedical-digital-kit 

 

im märz sollten die zahlen des 4.quartals 2012 kommen. werden vermutlich stark ausfallen aufgrund des retroaktiven charakters der kommissionen seitens ge-healthcare. 

 

so langsam scheint die betreuung durch kcsa erste früchte zu tragen. neben der neu gestalteten website,

vasomedical.com

 

der investor call am 07.02.

ariva.de/news/Life-Sciences-and-Healthcare-Companies-Join-to-Webcast-Live-on-February-7th-at-RetailInvestorConferences-com-4426158 

 

sowie die positive darstellung der performance auf der messe in dubai in einen neu ins leben gerufenen blog

www.vasomedical.com/blog/2013/02/04/...e-2013-arab-health-exhibition/

die darstellung als neu geborene firma gefällt mir.

 

 

aus einem anderen bord, fragen und antworten von ýthe smalls<-- and >bocamp< 

 

 

here were the questions and answers as fast as i could type them. i am not a typist by any stretch. i paraphrased to keep up. if you have any questions or want more detail - i will try to provide. other than bocamp and i - anyone else listen/watch?

Q 1: Can you break out revenue by segment.
A1: Based on shareholder inquiry we may provide more detail/breakout in next reporting but can not here due to limited disclosure

Q2: Will company use stock as currency for future acquisition?
A1: Yes or no depending on company position. We are careful on how we use cash and we have private equity partners for M&A. Acquistiion targets may want to participate on our equity growth. Chance they will. Don’t expect all stock deals. Stock and cash combination.

Q3: Who are your ECP competitors?
A3: Domestically: three in US based on FDA clearance. (Didn’t catch the names). VASO thinks they are about 70% marketshare. Other three companies are all private.
Internationally – market share is assumed higher. China competitors are more active. Ma visited one competitor in China

Q4: How many shares outstanding.

Q5: Ownership structure
A5: Insiders own about 47% of outstanding shares

Q6: Please discuss competitive environments for ECP offerings
A6: Competition on two fronts: other ECP manufacturers and with other procedures. Mainly PCI and Bypass Surgery. EECP is a low cost solution compared to PCI and Bypass. Has potential to save healthcare system billions of dollars. May not work for some doctors where they charge higher – pure economics. Try to get support from politicians, consumers, etc to save healthcare system.

Q7: Can you please discuss current cash balance and additional funding needs for 2013?
A7: Annual results for 2012 will be filed in “due time – I think next month”. Not in position to disclose our results for year end 2012. As I Mentioned in presentaino – cash and cash equivalents at the end of 3Q12 is $10MM. Maintaining a good cash balance since 2H12. If we continue operation as is – I do not forsee any additional spending of cash. However, given our growth strategy and M&A- we are very careful with our cash spending and we may need additional cash funding – particulary related to M&A. We are actively discussing the need with interested parties and will disclose the results as they become necessary.

Q8: I would like to know about your catalysts for growth in 2013
A8: With current business – we should exhibit organic growth in both EECP and Biox in China and US markets. We should see stabilization and further growth in Vaso Healthcare. If you view the slides, we have put together growth strategy …M&A and equipment will be major catalysts for growth.

Q9: What is the source of growth in cash balance in 2011 and 2012?
A10: Cash growth mainly in GE Healthcare diagnostics/imaging business.

Q11: Is a stock buyback being considered to show insider?
A11: Ma is confident with company and I am waiting to buyback some personally. With the insiders – they are almost always blacked out from buying because of material events in the works. Company buyback – technically it is difficult because the very low volume. Need to further consult SEC R&R concerning buyback. It will be a very lengthy discussion.

Q12: With the initial 2 year agreement with Rios coming to a close – where does VASO go from here? Will US continue to lag China and

A12: Edgary agreement is still active and will come to a conclusion in a couple of months. We do not have a conclusion at this moment and still actively working with them. We have conducted a thorough review of the situation. We have a strategy to for actions to change the …we are in the process of wrapping up and providing guidance to the public. If you will be patient – we will provide a summary to the public in a couple weeks.
A12: Yes and no. US leads and market acceptance will spill over. Other countries can’t perform expensive, more invasive procedures will be skipped for more economical ones like EECP. So market advantage. VASO is only one that is clearly documented.

 

 www.retailinvestorconferences.com">www.retailinvestorconferences.com"> www.retai...rconferences.com 

Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com



PR Newswire

NEW YORK, Feb. 11, 2013

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.  

 www.retailinvestorconferences.com

Vasomedical's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

 

http://ariva.de/news/...wing-at-RetailInvestorConferences-com-4432077  

Am 1.April kommen die Zahlen!! 

 

finance.yahoo.com/news/vasomedical-report-fourth-quarter-end-130000253.html 

 

 

 

Zahlen werden vor Markteröffnung veröffentlicht. Anschließend findet um 1pm eine Konferenzschaltung statt. Teilnahme möglich über die Website, vasomedical.com oder der IR über kcsa.com .

 

Die Spannung steigt.

 

Reports 34% Year-over-Year Increase in Equipment Segment Revenues for 2012  dafür rückgang seitens der kommissionen. mal sehen was der Markt draus macht.

 

finance.yahoo.com/news/vasomedical-announces-financial-results-fourth-120000585.html

 

 

 

Endlich kaufen sie eigene Aktien!

finance.yahoo.com/news/vasomedical-announces-share-repurchase-program-121500287.html

WESTBURY, N.Y., April 1, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO), announced today that its Board of Directors has authorized a share repurchase program of up to $1.5 million of the Company's common stock. As of Friday, March 29, 2013, this would represent approximately 5% of the total outstanding shares of Vasomedical common stock.

"We have the capital resources available to implement a fairly aggressive stock repurchase program such as this, which amounts to roughly 5% of our total outstanding shares, and still invest in our company's business to drive future growth. We believe that our share price does not properly reflect the current value of our business or its potential future performance," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "We have a strong financial profile that gives us the flexibility to focus on our future plans to grow sales and achieve profitability, while supporting our stock. We believe this strategy shows our commitment to building shareholder value as well as confidence in achieving long-term growth."  

The share repurchase program is effective immediately. Repurchases will be made in accordance with applicable securities laws in the open market or in privately negotiated transactions. Depending on market conditions and other factors, these repurchases may be commenced or suspended from time to time without prior notice. The Company is under no obligation to fulfill the entire amount of the stock buyback program approved by the Board.

 

 sales increased by $1,713,000,

or 69%, to $4,191,000 for the year ended December 31, 2012 as compared to $2,478,000 for the year ended December 31, 2011. The increase in equipment sales is due primarily to a $1,059,000 increase in sales by FGE, as well as a 92% increase in international EECP� sales, driven by increased volume and higher average selling price, partially offset by a 4% decrease in domestic sales, mainly a net result of lower deliveries and higher average selling price.

 

News; zur Absicht reformwillige Politiker über die Vorteile einer nicht invasiven und ökonomischen Behandlung von Herz Patienten zu informieren. 

Die Firma macht immer mehr dieser Dinge die von Aktionären lange vorgeschlagen wurden.

1.PR-Firma

2. Aktienrückkauf

3.  Politiker informieren

Vasomedical Introduces Policy Makers Focusing on Healthcare Reform to EECP® Therapy
Company Invites Congressmen to Local EECP Therapy Centers to Educate Them about How Non-Invasive Treatment Can Save the Healthcare System Millions

finance.yahoo.com/news/vasomedical-introduces-policy-makers-focusing-123000692.html

 

 

Der sehr zurInformationen vor einem Jahr, dass der Dr. Jun Ma plant: ca 10-15k EECP Maschinen zu verkaufen p.a.

Dies wurde in amerikanischen
Foren als sehr konservativ gewertet. Ok!
Aber 10-15k verkaufte Maschinen sind ne Hausnummer sondergleichen.
...wenn man den Preis und Anzahl mit KGV gegenüberstellt.

Margen variieren. Zwischen 400, und 5% ist bei Gewinnmargen ziemlich viel drin.

Gehen wir mal von 15% aus, bei einem Kaufpreis von 50.000$ den ich für bisher als günstig bewerte:

50.000$ * 0,15% = 7500$

Bei 7,5k$ pro verkaufter Einheit und bei einem angesetzten Ziel von 10-15K verkauften Einheiten per Anno ergibt sich ein phänomenales Ergebnis.

50.000$ * 15% * 10.000 (-15.ooo)verkauften Einheiten= 75000000$

75mio$ Gewinn bei 15% Margen entsprechen bei aktuell
(Aktienrückkauf nicht berücksichtigt)
162mio shares:

75mio$/162mio=0,462$ pro Aktie!!!

Bei einem (für einen Wachstumswert) konservativem Kurs Gewinn Verhältnis von 12!!
ergäbe sich hiermit ein Kurs von 0,46$*12=5,52$

Dann ist das Ding zurück an der Nasdaq und macht auch "Klick" bei den anderen.
....nur mal ne Überlegung...